Mylan agreed to pay $96.5 million in Provigil antitrust class action

Mylan NV has agreed to pay $96.5 million to settle claims by drug purchasers that it delayed launching a generic version of Cephalon Inc’s narcolepsy drug Provigil in exchange for payment from Cephalon. More »